Clinical Trial Update: Tucatinib Together With Pembrolizumab and Trastuzumab [Phase 2]

View source ↗

Summary

APhase 2 trial evaluating tucatinib in combination with pembrolizumab and trastuzumab for HER2-positive breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• KEYTRUDA (PEMBROLIZUMAB)
• Tukysa (tucatinib)

Snippet

Sponsor: Breast Cancer Trials, Australia and New Zealand | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: TERMINATED